Related Experiment Video
Updated: Mar 20, 2026

09:06
Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
Published on: February 3, 2023
2.0K
D-Peptides as Recognition Molecules and Therapeutic Agents
1Key Laboratory of Smart Drug Delivery (Fudan University)Ministry of Education Department of Pharmaceutics School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai 201203 (P. R. China).
Summary
D-peptides offer enhanced stability, bioavailability, and binding compared to L-peptides. This review explores the design and applications of these promising D-peptide therapeutic agents.
Area of Science:
- Biochemistry
- Medicinal Chemistry
- Pharmacology
Background:
- D-peptides are isomers of naturally occurring L-peptides, differing in chirality.
- Recent research highlights unique advantages of D-peptides over their L-counterparts.
- These advantages include improved pharmacokinetic and pharmacodynamic properties.
Purpose of the Study:
- To review the design principles of biologically active D-peptides.
- To explore the diverse applications of D-peptides in medicine and research.
- To highlight the potential of D-peptides as therapeutic agents.
Main Methods:
- Literature review of studies on D-peptide synthesis and characterization.
- Analysis of research investigating D-peptide interactions with biological targets.
- Compilation of data on D-peptide stability, bioavailability, and efficacy.
Main Results:
- D-peptides exhibit superior enzymatic stability compared to L-peptides.
- D-peptides demonstrate prolonged plasma half-life and enhanced oral bioavailability.
- Improved binding affinity and specificity of D-peptides to target proteins have been observed.
Conclusions:
- D-peptides represent a promising class of molecules with significant therapeutic potential.
- Their enhanced properties make them attractive alternatives to traditional L-peptide drugs.
- Further research into D-peptide design and application is warranted.
Related Concept Videos
Transducer Mechanism: Enzyme-Linked Receptors
4.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
4.8K
Glucagon-like Receptor Agonists
1.2K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.2K

